¹**Characteristics and Determinants of Pulmonary Long** ²**COVID**

- 3
- 4 Michael John Patton^{1,2†}, Donald Benson⁴, Sarah W. Robison³, Raval Dhaval³, Morgan L.
- 5 Locy³, Kinner Patel³, Scott Grumley⁴, Emily B. Levitan⁵, Peter Morris³, Matthew Might²,
- 6 Amit Gaggar^{3,6‡*}, and Nathaniel Erdmann^{7‡}
- 7
- 8 Medical Scientist Training Program, Heersink School of Medicine, University of 9 Alabama at Birmingham, Birmingham, AL, USA
- ² Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham,
- 11 Birmingham, AL, USA
- ³ Department of Medicine, Pulmonary, Allergy, & Critical Care Medicine Division,
- 13 University of Alabama at Birmingham, AL, USA
- ⁴ Department of Radiology, University of Alabama at Birmingham, AL, USA
- ⁵ Department of Epidemiology, University of Alabama at Birmingham, AL, USA
- 16 ⁶ Birmingham VA Medical Center, Pulmonary Section, Birmingham, AL, USA
- ⁷ Department of Medicine, Division of Infectious Diseases, University of Alabama at
- 18 Birmingham, AL, USA
- ¹⁹† First Author
- 20 \neq Co-senior Authors
21 \rightarrow Corresponding Aut
- 21 * Corresponding Author
- 22
- 23 Michael John Patton, BA, MD,PhD candidate, mjpatton@uab.edu
- 24 Donald Benson, MD, PhD, donaldbenson@uabmc.edu
- 25 Sarah W. Robison, MD, srobison@uabmc.edu
- 26 Raval Dhaval, MD, draval@uabmc.edu
- 27 Morgan L. Locy, MD, PhD, mllocy@uabmc.edu
- 28 Kinner Patel, MD, kinnerpatel@uabmc.edu
- 29 Scott Grumley, MD, sgrumley@uabmc.edu
- 30 Emily B. Levitan, ScD, emilylevitan@uabmc.edu
- 31 Peter Morris, MD, pmorris@uabmc.edu
- 32 Matthew Might, PhD, might@uab.edu
- 33 Amit Gaggar*, MD, PhD, Email: agaggar@uabmc.edu, Address: Bevill Research
- 34 Building, 845 19th Street South, Birmingham, AL, 35294, Phone: 205-934-4304
- 35 Nathaniel Erdmann, MD, PhD, nberdmann@uabmc.edu
- 36
- 37
- 38 Word Count: 4777 (Abstract, Introduction, Results, Discussion, References, Legends)
- 39

40 **STRUCTURED ABSTRACT**

41 **RATIONALE**

42 Persistent cough and dyspnea are prominent features of post-acute sequelae of SARS-43 CoV-2 (termed 'Long COVID'); however, physiologic measures and clinical features 44 associated with these pulmonary symptoms remain poorly defined.

45 **OBJECTIVES**

46 Using longitudinal pulmonary function testing (PFTs) and CT imaging, this study aimed

47 to identify the characteristics and determinants of pulmonary Long COVID.

48 **METHODS**

49 The University of Alabama at Birmingham Pulmonary Long COVID cohort was utilized to 50 characterize lung defects in patients with persistent pulmonary symptoms after 51 resolution primary COVID infection. Longitudinal PFTs including total lung capacity (TLC) 52 and diffusion limitation of carbon monoxide (DLCO) were used to evaluate restriction 53 and diffusion impairment over time in this cohort. Analysis of chest CT imaging was 54 used to phenotype the pulmonary Long COVID pathology. Risk factors linked to 55 development of pulmonary Long COVID were estimated using univariate and 56 multivariate logistic regression models.

57 **MEASUREMENTS AND MAIN RESULTS**

58 Longitudinal evaluation 929 patients with post-COVID pulmonary symptoms revealed 59 diffusion impairment (DLCO ≤80%) and restriction (TLC ≤80%) in 51% of the cohort 60 (n=479). In multivariable logistic regression analysis (adjusted odds ratio; aOR, 95%

61 confidence interval [CI]), invasive mechanical ventilation during primary infection 62 conferred the greatest increased odds of developing pulmonary Long COVID with 63 diffusion impaired restriction (aOR=10.9 [4.09-28.6]). Finally, a sub-analysis of CT 64 imaging identified evidence of fibrosis in this population.

65 **CONCLUSIONS**

66 Persistent diffusion impaired restriction was identified as a key feature of pulmonary 67 Long COVID. Subsequent clinical trials should leverage combined symptomatic and 68 quantitative PFT measurements for more targeted enrollment of pulmonary Long COVID 69 patients.

- 70
- 71
- 72
-
- 73
- 74
- 75
- 76
-
- 77
- 78
- 79
-
- 80
- 81
- 82
-
- 83

84 **INTRODUCTION**

85 A major consequence of the COVID-19 pandemic has been the complex and 86 frequently debilitating post-acute sequelae of SARS-CoV-2 infection (PASC, also termed 87 The COVID'), estimated to occur in 10% of patients after primary infection.^{1,2} To date, 88 over 150 distinct Long COVID symptoms involving every major organ system have been 89 reported.³ Recent efforts to develop a consensus definition for Long COVID using 90 symptom clustering have highlighted broad disease sub-types associated with chronic 91 fatigue, post-exertional malaise, brain fog, and loss of smell or taste.⁴ These efforts 92 represent an important first step for Long COVID research; however, characterizing 93 discreet endotypes with widely available quantitative physiologic measurements is 94 essential for standardizing Long COVID diagnosis and management.

95 Prolonged pulmonary symptoms, notably dyspnea and cough, are among the most 96 commonly reported manifestations of Long COVID (hereon referred to as 'pulmonary 97 Long COVID'). $4-6$ Although pulmonary symptoms are frequently reported, the underlying 98 cause(s) and clinical trajectory of Long COVID patients suffering from these symptoms 99 remains unclear. Prior studies have suggested diffusion impairment that resolves within 100 1-year of hospitalization is a common feature of post-acute COVID-19.^{7–10} Other post-101 acute COVID follow-up studies have reported radiologic evidence of lung pathology 102 characterized by ground glass opacities and fibrotic changes.^{11–18} These results have 103 provided valuable insight into post-COVID lung pathology, but are limited by small cohort 104 size and inherently biased towards post-acute COVID patients, rather than Long COVID 105 populations presenting for persistent pulmonary complaints.

106 To address this knowledge gap, we leveraged a large, demographically diverse 107 cohort exclusively comprised of Long COVID patients experiencing pulmonary 108 symptoms persisting for ≥1 month after resolution of acute SARS-CoV-2 infection. Using 109 longitudinal pulmonary function testing (PFT) and computerized tomography (CT) 110 imaging, we identify specific disease features and risk factors linked to the development 111 of pulmonary Long COVID. These presentations capture the population of patients with 112 persistent clinical symptoms and reflect the natural history of pulmonary Long COVID. 113 Lastly, we provide evidence for a novel endotype of Long COVID defined by persistent 114 diffusion impairment and pulmonary restriction. 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129

130 **METHODS**

131 **Study Design and Population**

132 This single-center, retrospective cohort study was performed among adult patients (≥¹⁸ 133 years) with a positive COVID-19 PCR and/or rapid antigen test during the study window 134 (03/2020-08/2023), followed by self- or physician referral to the University of Alabama at 135 Birmingham (UAB) Post-COVID Pulmonary Clinic for complaint of unresolved respiratory 136 symptoms. Pulmonary Long COVID was defined as pulmonary symptoms persisting for ¹³⁷≥1 month that had developed ≥28 days after resolution of primary SARS-CoV-2 138 infection. Baseline (1st visit) PFTs and CT scans were defined by the first date of the 139 measurement within a window of 14-days prior to and 6-months after the patient's 1st 140 Long COVID clinic visit date. Follow-up measurements (termed 2nd and 3rd visit) were 141 restricted to the study window and had to occur after the first encounter measurement. 142 The cohort was stratified by percent predicted diffusion capacity for carbon monoxide 143 (DLCO; normal=DLCO >80%, impaired=DLCO ≤80%) and percent predicted total lung 144 capacity (TLC) in accord with the American Thoracic Society consensus definition for 145 restrictive lung disease. Lung restriction sub-groupings were (1) no restriction TLC 146 >80%, (2) mild restriction TLC 71-80%, (3) moderate restriction TLC 51-70%, (4) severe 147 restriction TLC ≤50%.^{19,20} All pulmonary function studies were conducted utilizing the 148 same equipment (VyntusTM system from Vyaire Medical Incorporated).

149

150

151

153 **Patient Variables Extracted from Electronic Medical Record and** 154 **Radiographic Images**

155 Clinical variables were extracted for all patients in the cohort including: advanced age 156 (≥65 years), biological sex, elevated BMI (≥30), smoking history (never, former, or 157 current smoker), pre-COVID vaccination status, ICU admission, COVID-19 severity 158 (assessed using the WHO score system representing maximum oxygen therapy support 159 required), and therapeutics (dexamethasone, remdesivir, days on a specific oxygen 160 support device) during primary infection, SARS-CoV-2 variant, and months from primary 161 infection to first Long COVID clinic visit.²¹ Pre-COVID comorbidities (renal, pulmonary, 162 heart failure or hypertension, diabetes, obstructive sleep apnea, and 163 immunosuppression) were determined by physician review of medical records. Chest 164 CT imaging was assessed by two blinded cardiothoracic radiologists for the presence or 165 absence of 6 pulmonary imaging findings: lung consolidation, ground-glass opacities, 166 reticulations, other fibrotic-like changes (i.e. architectural distortion, traction 167 bronchiectasis and honeycombing; termed 'other fibrosis'), bronchiectasis, and 168 emphysema (see eTable 3 for two-reader similarity evaluation). An overall severity score 169 was determined using a previously defined image CT scoring system quantifying 170 abnormalities in all 5 lung lobes with scores ranging from 0 (no involvement) to 25 171 (multi-lobe involvement).²² Detailed information on variables extracted can be found in 172 the supplemental materials (eTable 1).

173

175

176 **Statistical Analysis**

177 Cohort statistics were reported with mean ±standard deviation or median [Q1-Q3] in 178 Table 1. Alluvial diagrams were used to assess relative DLCO and TLC improvement or 179 decline in patients with 3-consecutive follow-ups visits (Figure 2C). Logistic regression 180 models (unadjusted variable and multi-variable adjusted) were used to discover risk 181 factors for developing diffusion impairment (DLCO≤80%) with severe or moderate 182 restriction (TLC≤70%) at 1st Long COVID clinic visit (Table 2; see eTable 1 for details on 183 model variables and eTables 5-7 for model sensitivity testing omitting patients without a 184 primary COVID infection hospitalization and patients with pre-existing pulmonary 185 comorbities). All modeling results are reported as either unadjusted (OR) or adjusted 186 odds ratios (aOR) with bootstrapped (n=1000 iterations) 95% confidence intervals (CI). 187 All statistical analyses were performed using R (version 4.2, R Foundation).

188

189

190

- 192
- 193
- 194
- 195 196
-
- 197
- 198

199

200 **RESULTS**

201 **Study Population**

202 A total of 1,097 patients with prolonged pulmonary symptoms after primary 203 SARSCoV-2 infection were identified based upon their evaluation in post-acute COVID 204 pulmonary clinic. After exclusion, 929 patients with prolonged pulmonary symptoms 205 (dyspnea, cough, or chest discomfort) lasting ≥1 month after resolution of primary 206 SARS-CoV-2 infection and a subsequent PFT were included in this study (Figure 1, 207 Table 1). To evaluate the role of pulmonary abnormalities in DLCO and evidence of pro-208 fibrotic processes, we stratified patients by diffusion impairment and severity of 209 pulmonary restriction as measured by first post-acute PFT. Median time from primary 210 SARS-CoV-2 infection to 1st Long COVID clinic visit was 125 days for diffusion impaired 211 patients and 148 days for patients with normal diffusion capacity (Table 1). Patient age 212 (mean, \pm SD) for the diffusion impaired group was 56 \pm 13 years compared to 48 \pm 14 years 213 in the normal diffusion group (Table 1). For both groups, the majority of primary SARS-214 CoV-2 infections occurred during the alpha-variant wave (range: 62-63%), followed by 215 21-23% and 15-16% occurring in the delta and omicron waves, respectively (eTable 2). 216 Differences in primary pulmonary symptom reported at 1st Long COVID clinic visit were 217 unremarkable between patients with and without diffusion impairment (range; dyspnea: 218 76-79%, cough: 17-19%, chest discomfort: 4%).

219 We sought to determine how acute disease severity contributed to PFT findings for 220 patients with pulmonary Long COVID. Acute disease severity was stratified by peak 221 WHO ordinal score. Of the 73 patients who required invasive mechanical ventilation

222 (IMV), only 3 were in the normal diffusion capacity group (Table 1). Increased frequency 223 and duration of oxygen support was observed among diffusion impaired patients with the 224 severe restriction group (IMV: 32%, HFNC: 22%) exceeding that of the moderate (IMV: 225 9%, HFNC: 16%), mild (IMV: 6%, HFNC: 14%), and no restriction groups (IMV: 3%, 226 HFNC: 5%; Table 1). A similar trend of increased time of oxygen therapy (median [Q1- 227 Q3]) during primary infection was also observed in diffusion impaired patients (IMV: 18 228 [8-35] days; HFNC: 5 [3-8] days, and nasal cannula: 7 [4-11] days; eTable 2). 229 Differences in vaccination, pre-existing pulmonary disease or obstructive sleep apnea, 230 and smoking history prior to primary SARS-CoV-2 infection were minimal between 231 diffusion impaired and normal groups (Table 1). Patients with diffusion impairment had a 232 greater proportion of pre-existing diabetes (21%) and heart failure or hypertension (52%) 233 compared to the normal diffusion group with 14% and 33%, respectively (Table 1). 234 Cumulative lung involvement (25 points total, 5 points per lobe; median [Q1-Q3]) was 235 higher in the diffusion impaired group (9 [1-17]) compared to the normal group (0 [0-2]). 236 The degree of lung involvement on CT imaging for diffusion impaired patients correlated 237 with increasing severity of lung restriction (none: 3 [1-7], mild: 3 [0-9], moderate: 7 [1-13], 238 severe: 17 [9-21]; Table 1). Further characteristics of the cohort are presented in Table 1 239 and eTable 2.

- 240
- 241
- 242
- 243
- 244
- 245

246

247

248 **Longitudinal Evaluation of Pulmonary Function Testing**

249 To assess physiological differences between patients with pulmonary Long COVID, 250 we evaluated longitudinal PFTs over three total Long COVID visits. After 1st visit 251 stratification, patients without diffusion impairment had, on average, normal lung 252 capacity during the visit 2 visits (TLC 1st: $82\pm15\%$, 2nd: $79\pm13\%$) with mild decline on 253 3rd visit (72±15%) compared to patients with diffusion impairment on respective follow-254 up visits (TLC 1st: 65±18%, 2nd: 65±15%, 3rd: 64±15%) (Figure 2A, eTable 4). Diffusion 255 impaired patients with severe or moderate restriction experienced little to no 256 improvement in TLC at 2nd (severe: 51±14%, moderate: 66±11%) or 3rd visit (severe: 257 55±14%, moderate: 65±12%) (Figure 2A, eTable 4). Overall, patients with normal 258 diffusion capacity at 1st visit maintained normal or above normal DLCO at the follow-up 259 visits (DLCO 1st: 95±12%, 2nd: 93±16%, 3rd: 90±15%), regardless of the level of 1st 260 visit restriction (Figure 2B, eTable 4). In contrast, patients with diffusion impairment at 1st 261 visit remained, on average, diffusion impaired at all follow-up visits (DLCO 1st: 59±16%, 262 2nd: 66±19%, 3rd: 65±19%), with a clear association between worsening TLC and 263 DLCO (Figure 2B, eTable 4). Additional PFT measurements are provided in eTable 4.

264 Alluvial diagrams were used to assess improvement or decline in diffusion 265 impairment and restriction for patients with 3-consecutive PFTs at the UAB pulmonary 266 Long COVID clinic (N=100, Figure 2C). Overall, we observed that the majority of 267 patients with diffusion impairment and severe or moderate restriction at 1st visit had 268 persistent restriction and diffusion impairment at 2nd and 3rd follow-up visits (Figure 2C). 269 Improvement from diffusion impairment at any level of restriction was rare, with only 5

270 patients regaining normal TLC and DLCO by their 3rd visit. Over half of the normal 271 diffusion capacity patients (n=11) had some level of lung restriction at 1st visit (n=1 mild, 272 n=9 moderate, n=1 severe). Restriction or diffusion impaired restriction were the 273 predominant phenotypes observed by the 3rd follow-up visit, thereby indicating an earlier 274 stage of disease followed by progression among the normal diffusion capacity patients 275 (Figure 2C).

276 **Risk Factors for Developing Pulmonary Long COVID with Severe**

277 **Pulmonary Restriction**

278 Logistic regression models were used to identify risk factors for developing Long 279 COVID with combined diffusion impairment (DLCO ≤80%) and severe or moderate 280 restriction (TLC ≤70%). Unadjusted univariable modeling revealed advanced age ≥⁶⁵ 281 years (OR=1.63 [1.23-2.23]), male sex (OR=1.88 [1.43-2.48]), renal disease (OR=2.48 282 [1.474.15]), diabetes (OR=1.82 [1.30-2.51]), heart failure or hypertension (OR=2.54 283 [1.98-3.32]), smoking history (OR=1.39 [1.03-1.86]), ICU admission (OR=6.15 [4.24- 284 9.36]), and use of nasal cannula (OR=4.21 [2.90-6.07]), high-flow nasal cannula 285 (OR=6.10 [3.92-9.82]), and invasive mechanical ventilation (OR=16.0 [8.87-34.4]) as 286 independent risk factors for developing pulmonary Long COVID with severe or moderate 287 restriction (Table 2). After adjusting for all variables, we observed that invasive 288 mechanical ventilation conferred the greatest increased odds of developing pulmonary 289 Long COVID with diffusion impairment and severe or moderate restriction (aOR=10.9 290 [4.09-28.6]), followed by nasal cannula (aOR=4.0 [2.61-6.33]) and high-flow nasal 291 cannula (aOR=3.86 [1.73-8.09]) use during primary SARS-CoV-2 infection, heart failure 292 or hypertension (aOR=2.09 [1.46-2.99]) and male sex (aOR=1.44 [1.03-1.98]; Table 2; 293 reference group: un-hospitalized primary infection patients). In a sub-analysis using only 294 hospitalized patients (WHO score 4-7), the association of invasive mechanical ventilation 295 with diffusion impairment and severe or moderate restriction was comparable with whole 296 cohort results (aOR=9.56 [3.22-32.6] vs. reference group of hospitalized room-air 297 patients; eTable 5). To evaluate the potential effect of patients with pre-existing 298 pulmonary comorbidities on our model results, further sensitivity testing was performed 299 (eTables 6-7). Overall, the results show that invasive mechanical ventilation still 300 conferred the greatest risk for development of pulmonary Long COVID with diffusion 301 impairment and severe or moderate restriction (eTable 6, cohort sans patients with 302 pulmonary comorbidities vs. reference group of non-hospitalized patients aOR=14.5 303 [5.0-50.9]; eTable 7 cohort sans patients pulmonary comorbidities vs. reference group of 304 hospitalized room-air patients aOR=15.2 [4.72-68.1]).

305

306 **Assessment of CT Imaging and Pathology**

307 CT imaging was performed on a total of 308 patients (33%; n=246 diffusion 308 impaired sub-group, n=62 diffusion normal sub-group; Table 1). CT pathology and 309 increased lung involvement were predominantly found in diffusion impaired patients with 310 severe or moderate restriction. CT scoring of images taken within 6-months of the 1st 311 Long COVID visit identified ground glass opacities (85%), reticulations (82%), 312 bronchiectasis (69%), and fibrotic changes (65%) as the defining pathologies in the 313 majority of diffusion impaired severe restriction patients (Figure 3A, eTable 2). A similar 314 pathologic profile was found in diffusion impaired patients with moderate restriction

- 339
- 340

342 **DISCUSSION**

343 Our current understanding of persistent pulmonary defects from SARS-CoV-2 344 infection are primarily derived from prospective follow-up studies assessing patient 345 outcomes after hospitalization with acute COVID-19. Gradual recovery of impaired 346 diffusion capacity (DLCO ≤80%) and radiographic evidence of fibrotic pulmonary tissue 347 are among the most commonly reported observations.^{7–10,23–27} Although these studies 348 offer key insights into the trajectory of acute COVID recovery, characterizing patients 349 without post-COVID symptoms limit the applicability of these findings to Long COVID 350 patients with persistent dyspnea, cough, and chest discomfort. To address this 351 knowledge gap, we leveraged a large, demographically diverse cohort comprised 352 exclusively of Long COVID patients with persistent pulmonary symptoms. For this 353 cohort, we aligned robust medical record data requiring no imputation, quantitative CT 354 imaging, and longitudinal pulmonary function testing (PFT) to identify the characteristics 355 and determinants of pulmonary Long COVID. Our study establishes a clear association 356 between burden of acute COVID disease and the development of persistent lung 357 restriction with diffusion impairment. Collectively, these results comprehensively define 358 pathology for Long COVID that can be readily measured with PFTs and provides 359 opportunity to better study the post-viral interplay of pulmonary symptoms with 360 alterations in lung physiology.

361 Demographic risk factors (aOR [95% CI]) associated with the development of 362 pulmonary Long COVID with diffusion impairment and severe or moderate restriction 363 included male sex (aOR=1.44 [1.05-2.00]) and pre-existing heart failure and 364 hypertension (aOR=2.07 [1.46-3.02]; Table 2, eTable 5). These findings differ from a

365 recent meta-analysis of multi-organ Long COVID symptoms that noted an elevated risk 366 in females (aOR=1.56) and individuals over 40 years of age (aOR=1.21).²⁸ Our findings 367 emphasize differences between the assessments obtained from broad symptom 368 observations and physiological readouts in pinpointing at-risk populations. In Long 369 COVID patients complaining of prolonged pulmonary symptoms, prior studies have 370 suggested that dyspnea is a major feature and that symptoms can persist for months 371 after initial infection.^{9,29} Our study affirmed this observation with 78% (n=725) of the UAB 372 pulmonary Long COVID cohort identifying dyspnea as the primary symptom, followed by 373 18% (n=167) with cough and 4% (n=37) with chest discomfort (Table 1). Notably, the 374 complaint of dyspnea remained consistent (>70%) across all degrees of diffusion 375 impairment, restriction, and levels of lung involvement seen on CT imaging (Table 1, 376 eTable 2). This suggests symptoms alone do not provide sufficient granularity to identify 377 distinct endotypes of pulmonary Long COVID, thereby highlighting the importance of 378 incorporating routine PFTs in the diagnostic evaluation of this patient population.

379 Our study demonstrates that the severity of hypoxia during primary SARS-CoV-2 380 infection is a critical factor in the development of pulmonary Long COVID with persistent 381 diffusion impairment and restriction (Table 2). Notably, the post-hospitalization PFT 382 impairments in pulmonary Long COVID contrast with previously described post ARDS 383 findings in non-COVID patients, where subjects predominately present with isolated 384 diffusion impairment which improves to normal levels over a 6 month-1 year period and 385 Iimited lung restriction at any time-point.^{30–33} In addition to marked differences in lung 386 physiology, the presence of reticulations, bronchiectasis, ground glass opacities, and 387 fibrotic changes in pulmonary Long COVID CT images are distinct from ARDS which has 388 been predominantly described by the presence of ground glass opacities and

389 reticulations.³² Cumulatively, our physiologic and radiographic evidence suggest that 390 pulmonary Long COVID is a pro-fibrotic disease process that is distinct from ARDS; 391 however, future studies are warranted and needed to further elucidate the differences.

392 The biologic mechanisms underlying these symptomatic, physiologic, and 393 radiographic changes are poorly understood, but there is increasing evidence that pro-394 fibrotic interstitial lung changes are occurring in dyspneic patients as early as 1 month 395 post-COVID infection.^{18,34–36} From a molecular perspective, several independent lines of 396 evidence have shown that altered immune function, dysregulation of systemic 397 neutrophilic signatures, and persistent inflammation and presence of viral antigens are 398 associated with Long COVID. $37-40$ While few studies have been conducted in the Long 399 COVID lung, a prior spatial transcriptomic lung autopsy study from COVID-19 acute lung 400 injury demonstrates a distinct fibro-proliferative phenotype relative to influenza 401 infection.⁴¹ If true, pulmonary fibrosis therapeutics like Nintedanib and Pirfenidone, which 402 have been sparingly used in post-COVID associated fibrosis, may be uniquely suited for 403 the subset of pulmonary Long COVID patients with diffusion impaired restriction.^{42,43,46} 404 This report provides novel definition of a distinct endotype of Long COVID and 405 emphasizes the need to stratify patients for targeted therapeutic and clinical 406 management.

407 This study has limitations. Due to the retrospective nature of the cohort, PFTs were 408 not taken before or during primary SARS-CoV-2 infection, and therefore could not be 409 compared to measurements taken at the first Long COVID clinic visit. While this large, 410 demographically diverse cohort offers a unique opportunity to characterize pulmonary 411 presentations of Long COVID, patients presented to the Long COVID clinic at different 412 time intervals after primary COVID infection, and follow-ups were limited to attended

413 visits. Similarly, inherent bias towards more severe disease is present in patients who 414 had CT imaging performed. Despite these limitations, the combination of an objective 415 physiologic metric in longitudinal PFTs and a previously established Long COVID 416 symptomatic signature provide an important foundation for future Long COVID studies.

417 Although dyspnea is present in a majority of pulmonary Long COVID patients, 418 reported symptoms were not representative of the degree of diffusion impairment and 419 restriction across the cohort.⁴⁴ The additional granularity provided with PFTs highlights 420 the utility of a broadly available clinical test to identify pulmonary endotypes associated 421 with persistent physiologic impairment. These insights underscore the need for medical 422 providers to incorporate PFT measurements as a routine step for evaluating Long 423 COVID patients with pulmonary complaints. Informed stratification of patients 424 experiencing pulmonary Long COVID is critical as this population is likely to require high 425 utilization of health care services and would likely benefit from early therapeutic 426 interventions.⁴⁵

- 427
- 428
- 429
- 430
- 431
- 432
- 433
- 434
-
- 435
- 436

437

438

440 **ACKNOWLEDGEMENTS**

441 **AUTHOR CONTRIBUTIONS**

442 Michael John Patton (MJP), Nathaniel Erdmann (NE), Donald Benson (DB), Scott 443 Grumbley (SG), Emily B. Levitan (EBL), Amit Gaggar (AG), Sarah W. Robison (SWR), 444 Raval Dhaval (RD), Kinner Patel (KP), Morgan L. Locy (MLL), Peter Morris (PM), and 445 Matthew Might (MM) co-conceived the project, prepared the main text, and oversaw the 446 UAB cohort creation. MJP processed and analyzed EMR data to create all tables and 447 figures in the main text and supplement of this manuscript. DB analyzed and scored CT 448 images. SG analyzed and scored a subset of CT images. We thank Dr. Jeanne 449 Marrazzo, Dr. Surya Bhatt, and Dr. Mark Dransfield for contributing critical comments 450 and additions to the main text and supplement. NE oversaw IRB approval from the 451 University of Alabama at Birmingham (UAB IRBs: 300006291, 300006205). NE, MM, 452 RD, and AG, obtained funding and supervised the overall study. All co-authors reviewed 453 and approved the final version of the manuscript.

454

455 **FUNDING & DISCLOSURES**

456 This work was supported by the National Institute of Allergy and Infectious Diseases

457 (AI156898, K08AI129705), the National Heart, Lung, and Blood Institute (HL153113, 458 OTA21-015E, HL149944), and the COVID-19 Urgent Research Response Fund 459 established by the Hugh Kaul Precision Medicine Network at the University of Alabama 460 at Birmingham. No co-authors have any disclosures.

461

462

463 **REFERENCES**

- 464 1. Ballering, A. V., van Zon, S. K. R., Olde Hartman, T. C., Rosmalen, J. G. M. &
- 465 Initiative, L. C. R. Persistence of somatic symptoms after COVID-19 in the
- 466 Netherlands: an observational cohort study. The Lancet 2022; 400**,** 452–461.
- 467 doi:10.1016/S0140-6736(22)01214-4
- 468 2. Bull-Otterson, L. et al. Post–COVID Conditions Among Adult COVID-19 Survivors
- 469 Aged 18–64 and 65 Years —United States, March 2020–November 2021. MMWR.
- 470 Morbidity and Mortality Weekly Report 71 2022**.** doi:10.15585/mmwr.mm7121e1
- 471 3. Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings,
- 472 mechanisms and recommendations. Nature Reviews Microbiology 2023; 21, 133–
- 473 146. doi:10.1038/s41579-022-00846-2
- 474 4. Thaweethai, T. *et al.* Development of a Definition of Postacute Sequelae of SARS-
- 475 CoV-2 Infection. The Journal of the American Medical Association 2023; 329, 1934–
- 476 1946. doi:10.1001/jama.2023.8823
- 477 5. Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months
- 478 of symptoms and their impact. EClinicalMedicine 2021; 38, 101019.
- 479 doi:10.1016/j.eclinm.2021.101019
- 480 6. Subramanian, A. et al. Symptoms and risk factors for long COVID in non-
- 481 hospitalized adults. Nature Medicine 2022; 28, 1706–1714. doi:10.1038/s41591- 482 022-01909-w
- 483 7. Wu, X. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in 484 patients following COVID-19-related hospitalisation: a prospective study. The

485 Lancet Respiratory Medicine 2021; 9, 747–754. doi:10.1016/S2213-

- 486 2600(21)00174-0
- 487 8. Huang, C. et al. 6-month consequences of COVID-19 in patients discharged from
- 488 hospital: a cohort study. The Lancet 2021; 397, 220–232. doi:10.1016/S0140-
- 489 6736(20)32656-8
- 490 9. Huang, L. et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal 491 cohort study. The Lancet 2021; 398, 747–758. doi:10.1016/S0140-6736(21)01755-
- 492 4
- 493 10. Evans, R. A. et al. Physical, cognitive, and mental health impacts of COVID-19 after 494 hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study The 495 Lancet Respiratory Medicine 2021; 11, 1275-1287. doi:10.1016/S2213-
- 496 2600(21)00383-0
- 497 11. Stewart, I. et al. Residual Lung Abnormalities after COVID-19 Hospitalization:
- 498 Interim Analysis of the UKILD Post-COVID-19 Study. American Journal of
- 499 Respiratory and Critical Care Medicine 2023; 207, 693–703.
- 500 doi:10.1164/rccm.202203-0564OC

501 12. Yu, J. Z. et al. Lung perfusion disturbances in nonhospitalized post-COVID with

- 502 dyspnea-A magnetic resonance imaging feasibility study. Journal of Internal
- 503 Medicine 2022; 292, 941–956. doi:10.1111/joim.13558
- 504 13. Watanabe, A. et al. One-year follow-up CT findings in COVID-19 patients: A
- 505 systematic review and meta-analysis. Respirology 2022; 27, 605–616.
- 506 doi:10.1111/resp.14311
- 507 14. Baillie, J. K. et al. Multiorgan MRI findings after hospitalisation with COVID-19 in the

- 528 21. Beigel, J. H. et al. Remdesivir for the Treatment of Covid-19 Final Report. The
- 529 New England Journal of Medicine 2020; 383, 1813–1826.
- 530 doi:10.1056/NEJMoa2007764
- 531 22. Pan, F. et al. Time Course of Lung Changes at Chest CT during Recovery from
- 532 Coronavirus Disease 2019 (COVID-19). Radiology 2020; 295, 715–721.
- 533 doi:10.1148/radiol.2020200370
- 534 23. Nirmal, A. S. et al. Delayed lung function testing after COVID-19 to detect persistent
- 535 lung function abnormalities The DELTA COVID-19 lung function study. Journal of
- 536 family medicine and primary care 2022; 11, 7351–7356.
- 537 doi:10.4103/jfmpc.jfmpc_703_22
- 538 24. Stockley, J. A. et al. Lung function and breathing patterns in hospitalised COVID-19
- 539 survivors: a review of post-COVID-19 Clinics. Respiratory Research 2021; 22, 255.
- 540 doi:10.1186/s12931-021-01834-5
- 541 25. Salem, A. M. et al. The Long-Term Impact of COVID-19 Pneumonia on the
- 542 Pulmonary Function of Survivors. International journal of general medicine 2021;
- 543 14, 3271–3280. doi:10.2147/IJGM.S319436
- 544 26. Stylemans, D. et al. Evolution of lung function and chest CT 6 months after COVID-
- 545 19 pneumonia: Real-life data from a Belgian University Hospital. Respiratory
- 546 Medicine 2021; 182, 106421. doi:10.1016/j.rmed.2021.106421
- 547 27. González, J. et al. Pulmonary Function and Radiologic Features in Survivors of
- 548 Critical COVID-19: A 3-Month Prospective Cohort. Chest 2021; 160, 187–198.

549 doi:10.1016/j.chest.2021.02.062

- 551 Systematic Review and Meta-analysis. JAMA internal medicine 2023; 183, 566–
- 552 580. doi:10.1001/jamainternmed.2023.0750
- 553 29. Cares-Marambio, K. et al. Prevalence of potential respiratory symptoms in survivors
- 554 of hospital admission after coronavirus disease 2019 (COVID-19): A systematic
- 555 review and meta-analysis. Chronic Respiratory Disease 2021; 18.
- 556 doi:10.1177/14799731211002240
- 557 30. Herridge, M. S. et al. One-year outcomes in survivors of the acute respiratory
- 558 distress syndrome. The New England Journal of Medicine 2003; 348, 683–693.
- 559 doi:10.1056/NEJMoa022450
- 560 31. Herridge, M. S. et al. Functional disability 5 years after acute respiratory distress
- 561 syndrome. The New England Journal of Medicine 2011; 364, 1293–1304.
- 562 doi:10.1056/NEJMoa1011802
- 563 32. Masclans, J. R. et al. Quality of life, pulmonary function, and tomographic scan 564 abnormalities after ARDS. Chest 2011; 139, 1340–1346. doi:10.1378/chest.10-2438
- 565 33. Lindén, V. B., Lidegran, M. K., Frisén, G, Dahlgren, P, Frenckner, B. P. & Larsen, F.
- 566 ECMO in ARDS: a long-term follow-up study regarding pulmonary morphology and
- 567 function and health-related quality of life. Acta Anaesthesiologica Scandinavica
- 568 2009; 53, 489–495. doi:10.1111/j.1399-6576.2008.01808.x

- 570 Collen, J. F. Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current
- 571 Pandemic. Journal of clinical medicine 2021; 10. doi:10.3390/jcm10112452
- 572 35. McGroder, C. F. et al. Pulmonary fibrosis 4 months after COVID-19 is associated
- 573 with severity of illness and blood leucocyte telomere length. Thorax 2021; 76,
- 574 1242–1245. doi:10.1136/thoraxjnl-2021-217031
- 575 36. Bazdyrev, E., Rusina, P., Panova, M., Novikov, F., Grishagin, I. & Nebolsin, V. Lung
- 576 Fibrosis after COVID-19: Treatment Prospects. Pharmaceuticals (Basel,
- 577 Switzerland) 2021; 14. doi:10.3390/ph14080807
- 578 37. Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. & Boyton, R. J. The
- 579 immunology of long COVID. Nature Reviews Immunology 2023; 23, 618-634.
- 580 doi:10.1038/s41577-023-00904-7
- 581 38. George, P. M. et al. A persistent neutrophil-associated immune signature
- 582 characterizes post-COVID-19 pulmonary sequelae. Science Translational Medicine
- 583 2022; 14(671):eabo5795. doi:10.1126/scitranslmed.abo5795
- 584 39. Files, J. K. et al. Duration of post-COVID-19 symptoms is associated with sustained
- 585 SARS-CoV-2-specific immune responses. Journal of Clinical Investigation Insight
- 586 2021; 6(15):e151544. doi:10.1172/jci.insight.151544
- 587 40. Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J. & Ho, A. SARS-CoV-2,
- 588 SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and
- 589 infectiousness: a systematic review and meta-analysis. The Lancet Microbe 2021;
- 590 2, e13–e22. doi:10.1016/S2666-5247(20)30172-5

- 591 41. Margaroli, C. et al. Spatial mapping of SARS-CoV-2 and H1N1 lung injury identifies
- 592 differential transcriptional signatures. Cell reports Medicine 2021; 2, 100242.
- 593 doi:10.1016/j.xcrm.2021.100242
- 594 42. Zhou, X. et al. Case Report: Pirfenidone in the Treatment of Post-COVID-19
- 595 Pulmonary Fibrosis. Frontiers in medicine 2022; 9:925703.
- 596 doi:10.3389/fmed.2022.925703
- 597 43. Saiphoklang, N., Patanayindee, P. & Ruchiwit, P. The Effect of Nintedanib in Post-
- 598 COVID-19 Lung Fibrosis: An Observational Study. Critical care research and
- 599 practice 2022; 9972846. doi:10.1155/2022/9972846
- 600 44. Perlis, R. H. et al. Prevalence and correlates of long COVID symptoms among US
- 601 adults. JAMA Network Open 2022; 5, e2238804.
- 602 doi:10.1001/jamanetworkopen.2022.38804
- 603 45. Cutler, D. M. The costs of long COVID. JAMA Health Forum 2022; 3, e221809.
- 604 doi:10.1001/jamahealthforum.2022.1809
- 605 46. Sgalla G, Leone PM, Gualano G, Simonetti J, Comes A, Verdirosi D, Di Gennaro F,
- 606 Larici AR, Ianniello S, Cicchetti G, Fusco N, Pani M, Palmieri F, Richeldi L. A
- randomized trial of pamrevlumab in patients with COVID -19
608 pneumonia. Respirology 2023; doi:10.1111/resp.14575.

- 608 pneumonia. Respirology 2023; doi:10.1111/resp.14575.
- 609
- 610
- 611
-
- 612
- 613
- 614

615 **FIGURES & TABLES**

616 **Figure 1: Accrual of Long COVID Patients with Persistent Pulmonary Symptoms** 617

aPrimary SARS-CoV-2 infection was defined as a positive result from a rapid antigen and/or polymerase chain reaction (PCR) test between 03/01/2020 - 08/01/2023

^bPercent predicted diffusion capacity for carbon monoxide (DLCO) and total lung capacity (TLC) was assessed at the 1st pulmonary Long COVID clinic visit

Table 1: Characteristics of Pulmonary Long COVID Patients Stratified by 1st Visit Diffusion Capacity and Restriction in the UAB Cohort

Table 1: Characteristics of Pulmonary Long COVID Patients Stratified by 1st Visit Diffusion Capacity and Restriction in the UAB Cohort

Statistics are reported as n, $\left(\% \right)$ unless otherwise specified by $\left(\frac{1}{2} \text{Mean} \pm \text{SD} \right)$ or $\left(\frac{2}{1 - \text{Q}} \right)$

N=total patients per diffusion capacity stratification group, n=total patients per restriction stratification group

Lung Involvement was assessed with a 0-5 scale (0=no involvement, 1=1-5%, 2=5-25%, 3=25-50%, 4=50-75%, 5≥75%)

 Abbreviations: TLC, percent predicted total lung capacity; DLCO, diffusion limitation of carbon monoxide; CT, computerized tomography; WHO, World Health Organization; COVID, coronavirus disease; UAB, University of Alabama at Birmingham

Figure 2: Diffusion Impaired Restriction is a Key Feature of Persistent Pulmonary Long COVID

Figure 2 Legend: (A-B) Results of percent predicted total lung capacity (TLC) and diffusing capacity for carbon monoxide (DLCO) are shown for 3 clinic visits with stratification by restriction severity (color) measured during the 1st visit PFT and presence or absence of diffusion impairment (hashed lines). Boxplots represent the median black center line; 25th and 75th percentile box boundaries) for each PFT measured, with number of patients (N) reported below each group. Normal TLC and DLCO are denoted by the grey color on the plot at 80%. (C) Alluvial diagram displays patient PFT trajectories over 3-consecutive visits (N=100 total) with relative improvement or decline as measured by TLC (color) and DLCO (hashed lines). Labelling of alluvial diagram axes groups with <5 patients was omitted for visual clarity.

Table 2: Risk Factors for Pulmonary Long COVID with Diffusion Impaired Restriction

1 Unadjusted odds ratio (OR) and adjusted odds ratio (aOR), 95% confidence interval (n=1000 bootstraps)

²Diffusion impaired restriction is defined by a DLCO ≤80% and a TLC ≤70% measured by PFT at the 1st Long COVID clinic visit

Figure 3: CT Image Findings in Pulmonary Long COVID with Diffusion Impaired Restriction

Figure 3 Legend: (A-D) Representative CT images of pulmonary Long COVID patients with diffusion impairment (DLCO ≤80%) with severe (TLC ≤50%), moderate (TLC 51-70%), mild (TLC 71-80%), and no restriction (TLC >80%) assessed at the 1st Long COVID clinic visit. Corresponding barcharts of CT pathology (%, N=patients) are displayed for each group. (Note: architectural distortion, traction bronchiectasis and honeycombing are termed 'Other Fibrosis').